A plain language summary of daratumumab plus lenalidomide / bortezomib / dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
This plain language summary published in Future Oncology describes results for the Black participants of the GRIFFIN clinical study, which looked at the treatment combination of daratumumab plus a standard therapy for multiple myeloma (called RVd therapy).
Read the full article here.
The original article on which this plain language summary is based is titled ‘Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN’ and was published in Blood Cancer Journal. Read the original article here.